Figure 7.

Pharmacologic inhibition of NE mitigates diabetes-induced abnormalities in retinal superoxide (A) and expression of pro-inflammatory proteins (B–D), as well as leukocyte-mediated cytotoxicity to retinal endothelial cells (E). Sivelestat was administered IP daily at a dosage of 0.3 or 2.0 mg/kg/day. Similar results were shown in diabetic mice treated with other two NE inhibitors – GW311616A (GW) at a dosage of 4 mg/kg/injection twice a week and alvelestat (Alv) at a dosage of 2 mg/kg/day (F–I). Total duration of diabetes was 10 weeks, drug treatment was 8 weeks. Data are expressed as mean ± SD. Graphs represent the combined results of 2 to 3 experiments; n = 4 to 8 per group; P < 0.05 is significant.